We are devoted to strengthening emerging pharmaceutical markets. To this end, we commit to upholding essential principles in all of our dealings with clients. Our Client Charter is our promise to you that ...
Our Quality Edge is how we blend Empathy, Reliability and Responsiveness to deliver exceptional service to all our clients.
We Partner with Clients to execute Outcomes Research in emerging markets.
We develop results-driven market access solutions for clients in emerging markets.
We are devoted to strengthening emerging pharmaceutical markets.
Market Access Solutions
Innovative Access Strategies
Our Quality Edge
Allegations of generic drug price fixing are troubling. phrmaccess.com/x/f2 pic.twitter.com/4C7AorOXx5
Yesterday from Carapinha & Company's Twitter
Paying Cash For Prescriptions Could Save You Money 23% Of Time, Analysis Shows. phrmaccess.com/x/ez pic.twitter.com/nqOBuvfflG
Why the Pharmaceutical Industry is Booming in Japan. phrmaccess.com/x/eq pic.twitter.com/cG5eyStJcy
About 4 days ago from Carapinha & Company's Twitter
FDA commissioner decries drug industry oligopoly. phrmaccess.com/x/eu pic.twitter.com/AQ2M7yWqoR
Novartis CEO: We Need a Different Approach to Drug Discovery. phrmaccess.com/x/er pic.twitter.com/cNKK1kuQuk
Risk Sharing, Italian Style. phrmaccess.com/x/eh pic.twitter.com/ccDajxmRgZ
About 5 days ago from Carapinha & Company's Twitter
We need to reach a common understanding about real world data. phrmaccess.com/x/el pic.twitter.com/JD3ggoctsB
New Study Questions Evidence for NCCN Recommendations. phrmaccess.com/x/en pic.twitter.com/sPZReVz9bI
Get your message out to an international audience. Shout Out Campaign. carapinha.com/contact-us-2/ pic.twitter.com/lOLbOUxokx
About 6 days ago from Carapinha & Company's Twitter
Drug Pricing Debate: Panel Talks About Transparency, Legislation. phrmaccess.com/x/ee pic.twitter.com/RM9cKWC9d9
Extra efforts made to ensure drug stockpiles (Qatar). phrmaccess.com/x/eg pic.twitter.com/LdbgaU460d
Probe Into Generic Drug Price Fixing Set To Widen. phrmaccess.com/x/e4 pic.twitter.com/fxCAUyBnNc
Last week from Carapinha & Company's Twitter
FDA’s Gottlieb blames industry ‘Kabuki drug pricing’ for high costs. phrmaccess.com/x/e6 pic.twitter.com/LRTasdqGAm
Shifts to generic drugs likely cut medical costs ¥1.3 trillion in ’17. phrmaccess.com/x/e0 pic.twitter.com/zTx4ZY9a9Y
About a week ago from Carapinha & Company's Twitter
Real-World Evidence Not Quite Believable Enough. phrmaccess.com/x/ds pic.twitter.com/qSdfCcrn60
About 2 weeks ago from Carapinha & Company's Twitter